General Information of Drug (ID: DMDEL3F)

Drug Name
EMZ701 Drug Info
Synonyms Interferon enhancing therapy
Indication
Disease Entry ICD 11 Status REF
Hepatitis B virus infection 1E51.0 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMDEL3F

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MEDI-546 DMPKWR3 Ovarian cancer 2C73 Phase 2 [3]
R-IFN-1a DMO9QB8 Hepatitis C virus infection 1E51.1 Phase 2 [4]
Belerofon DM9R0VA Hepatitis C virus infection 1E51.1 Phase 1 [5]
Omega interferon DMX6GFR Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [6]
BLX-883 DMR7WYX Hepatitis C virus infection 1E51.1 Discontinued in Phase 1 [7]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interferon alpha/beta receptor 1 (IFNAR1) TTSYFMA INAR1_HUMAN Modulator [2]

References

1 Clinical pipeline report, company report or official report of Transition Therapeutics.
2 Patent EP2766021 A1.
3 Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody. MAbs. 2015;7(2):428-39.
4 Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci.1999 Oct 15;168(2):131-6.
5 WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same.
6 Human interferon omega--a review. Mult Scler. 1995;1 Suppl 1:S44-7.
7 Patent CN103536906 A.